ENOV · Enovis Corporation
$19.29
+4.78% last session
End-of-day data · close of 2026-09-11
Market cap
$1B
Enterprise value
$2B
Trailing P/E
—
Forward P/E
5.0
Dividend yield
—
Beta
1.43
Avg volume
1M
Employees
8K
Daily Change %
4.78%
5 Days Change
2.53%
10 Days Change
-22.61%
30 Days Change
-22.64%
60 Days Change
-26.10%
Month to Day Change
-7.31%
Year to Day Change
-28.57%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — ENOV
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-09-02
Latest call per bank · past 12 months
Wells Fargo
Overweight$33.00
+79.3% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-02 | Wells Fargo | Maintains | Overweight | $39.00 → $33.00 |
| 2026-09-02 | Citizens | Maintains | Market Outperform | $55.00 → $47.00 |
| 2026-09-02 | Freedom Capital Markets | Maintains | Buy | $41.00 → $36.00 |
| 2026-09-01 | BTIG | Maintains | Buy | $40.00 → $36.00 |
| 2026-08-17 | Canaccord Genuity | Maintains | Buy | $50.00 → $45.00 |
| 2026-08-07 | Wells Fargo | Maintains | Overweight | $40.00 → $39.00 |
| 2026-08-06 | BTIG | Maintains | Buy | $39.00 → $40.00 |
| 2026-07-09 | BMO Capital | Initiates | Outperform | $0.00 → $29.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-09-11
- RSI (14): RSI is 35 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 23.8% below the 50-day MA ($25.31).
- Price vs 200-day MA: Trading 21.5% below the 200-day MA ($24.56).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is negative (-0.51) — short-term momentum is fading.
- 52-week range: Price is within 10% of the 52-week low ($18.41).
ENOV Price Chart
Loading chart for ENOV…
Fundamentals
About Enovis Corporation
Enovis Corporation, a medical technology company, focuses on developing clinically differentiated solutions in the United States and internationally. It operates through two segments: Prevention and Recovery, and Reconstructive segments. The Prevention and Recovery segment offers rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, electrical stimulators for pain management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions. The Reconstructive segment develops, manufactures, markets, and distributes surgical solutions that restore mobility and improve patient outcomes, which includes a range of differentiated implants, instrumentation, and enabling technologies used in elective and non-elective joint replacement, limb reconstruction, and foot and ankle procedures; and products for the hip, knee, shoulder, elbow, extremity reconstruction and fixation, foot, ankle, and finger, as well as surgical productivity tools. It also manufactures and distributes a range of products which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company distributes its products through independent distributors, direct salespeople, and patients. The company was formerly known as Colfax Corporation. Enovis Corporation was founded in 1995 and is headquartered in Wilmington, Delaware.
More in Medical Devices
ABT
Abbott Laboratories
$179B -14.4% YTD
MDT
Medtronic plc.
$117B -2.7% YTD
SYK
Stryker Corporation
$104B -21.2% YTD
BSX
Boston Scientific Corporation
$62B -52.8% YTD
EW
Edwards Lifesciences Corporatio
$50B 1.1% YTD
DXCM
DexCom, Inc.
$32B 26.4% YTD
GEHC
GE HealthCare Technologies Inc.
$29B -20.4% YTD
PHG
Koninklijke Philips N.V. NY Reg
$24B -4.0% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.